# Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients

> **NCT05164016** · — · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 21 (actual)

## Conditions studied

- Cancer
- Hematopoietic System--Cancer
- Transplant-Related Cancer
- Solid Tumor Malignancy
- Hematologic Malignancy
- Solid Organ Transplant
- Hematopoietic Cell Transplant
- Cellular Therapy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05164016
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-29
- **Primary completion:** 2025-05-01
- **Final completion:** 2026-04-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164016, "Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05164016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*